瑞巴派特联合雷贝拉唑治疗对医源性胃溃疡的疗效观察

Clinical observation of rebamipide therapy with rabeprazole in iatrogenic gastric ulcer patients after EMR

目的观察瑞巴派特联合雷贝拉唑治疗内镜下黏膜切除术(endoscopic mucosalresect,EMR)后医源性胃溃疡的有效性。方法 60例确诊为EMR后医源性胃溃疡的患者随机分成治疗组和对照组各30例,治疗组给予瑞巴派特联合雷贝拉唑治疗,对照组给予雷贝拉唑治疗。治疗4周后比较两组患者EMR后溃疡大小变化。结果治疗后4周,治疗组与对照组溃疡面积分别为(0.74±0.37)mm2、(1.38±0.69)mm2(P<0.01)。结论瑞巴派特联合雷贝拉唑对EMR术后医源性胃溃疡疗效确切。

Objective To investigate the effectiveness of rebamipide therapy with rabeprazole on iatrogenic gastric ulcer after endoscopic mucosalresect（EMR）.Methods 60 iatrogenic gastric ulcer patients after EMR were randomly allocated to two groups of 30 patients each and treated respectively with rebamipide 100mg thrice daily ＋ rabeprazole 20mg once a day and simple rabeprazole 20mg once a day for 4 weeks.Ulcer areas were evaluated.Results 4 weeks after EMR,the differences in ulcer areas between two groups were significant [（0.74 ± 0.37） mm2 vs（1.38 ± 0.69） mm2,P =0.000].Conclusions Rebamipide with rabeprazol is effective for the therapy of iatrogenic gastric ulcer after EMR.